Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases.
Purpose
To report two cases of thyroid eye disease (TED) associated compressive optic neuropathy (CON) that resolved after treatment with teprotumumab.


Observation
Two patients presented with active TED resulting in mild CON with the typical corresponding visual field (VF) defects. Both patients were initiated on intravenous (IV) corticosteroid therapy but despite treatment had persistent VF defects. Both patients were then treated with teprotumumab and demonstrated marked clinical improvement and complete resolution of TED-CON VF defects early in their infusion course.


Conclusions and importance
These cases suggest that teprotumumab can be a rapid and effective treatment for TED-CON, and raises the question of whether it may be superior to IV corticosteroid therapy.
['Chiou|Carolina A|CA|', 'Reshef|Edith R|ER|', 'Freitag|Suzanne K|SK|']
Teprotumumab Compressive optic neuropathy Thyroid eye disease Graves' disease Visual field defect